Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road
- PMID: 35876635
- DOI: 10.1158/1078-0432.CCR-22-1881
Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road
Abstract
A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population. See related article by Nagler et al., p. 4258.
©2022 American Association for Cancer Research.
Comment on
-
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis.Clin Cancer Res. 2022 Oct 3;28(19):4258-4266. doi: 10.1158/1078-0432.CCR-22-0809. Clin Cancer Res. 2022. PMID: 35670780
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
